These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23163663)

  • 21. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.
    Blonde L; Russell-Jones D
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():26-34. PubMed ID: 19878259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
    Armstrong MJ; Hull D; Guo K; Barton D; Hazlehurst JM; Gathercole LL; Nasiri M; Yu J; Gough SC; Newsome PN; Tomlinson JW
    J Hepatol; 2016 Feb; 64(2):399-408. PubMed ID: 26394161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide: a review of its use in type 2 diabetes mellitus.
    Croom KF; McCormack PL
    Drugs; 2009 Oct; 69(14):1985-2004. PubMed ID: 19747013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide: a review of its use in the management of type 2 diabetes mellitus.
    Perry CM
    Drugs; 2011 Dec; 71(17):2347-73. PubMed ID: 22085389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.
    Gluud LL; Knop FK; Vilsbøll T
    BMJ Open; 2014 Dec; 4(12):e005325. PubMed ID: 25526792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
    Armstrong MJ; Gaunt P; Aithal GP; Barton D; Hull D; Parker R; Hazlehurst JM; Guo K; ; Abouda G; Aldersley MA; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN
    Lancet; 2016 Feb; 387(10019):679-690. PubMed ID: 26608256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Kalogirou MS; Patoulias D; Haidich AB; Akriviadis E; Sinakos E
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101568. PubMed ID: 33309563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment evaluation of liraglutide in type 2 diabetes.
    Kela R; Davies MJ
    Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.
    Fonseca VA; Devries JH; Henry RR; Donsmark M; Thomsen HF; Plutzky J
    J Diabetes Complications; 2014; 28(3):399-405. PubMed ID: 24561125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.